ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Short Interest Update

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totalling 139,600 shares, a decline of 8.0% from the June 15th total of 151,700 shares. Currently, 0.7% of the company’s stock are sold short. Based on an average daily volume of 76,800 shares, the short-interest ratio is currently 1.8 days.

Hedge Funds Weigh In On ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC raised its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 24.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,281,305 shares of the company’s stock after purchasing an additional 253,052 shares during the period. Ingalls & Snyder LLC owned 4.87% of ImmunoPrecise Antibodies worth $2,191,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Price Performance

Shares of IPA stock traded down $0.10 during trading on Wednesday, hitting $0.88. The company’s stock had a trading volume of 60,568 shares, compared to its average volume of 315,398. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.38 and a current ratio of 1.66. The business has a fifty day moving average of $1.07 and a 200-day moving average of $1.41. ImmunoPrecise Antibodies has a 52 week low of $0.86 and a 52 week high of $2.84.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.